GHRS
What one share of GH Research holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression, or TRD.
GH Research’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.79 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.72 |
| Cash and investments | $3.97 |
| Debt | $0.00 |
| Book value | $4.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.01 | $0.00 | −$0.01 | — | $0.01 |
| 2020 | — | −$0.02 | $0.00 | −$0.01 | — | $0.20 |
| 2021 | — | −$0.21 | $0.00 | −$0.35 | — | $5.33 |
| 2022 | — | −$0.43 | $0.00 | −$0.50 | — | $4.80 |
| 2023 | — | −$0.68 | $0.00 | −$0.64 | — | $4.21 |
| 2024 | — | −$0.75 | $0.00 | −$0.81 | — | $3.44 |
| 2025 | — | −$0.79 | $0.00 | −$0.72 | — | $4.51 |